
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7457055/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study. CNS Spectrums, 2022, 27, 716-723.	1.2	3
2	A new machine learning-derived screening measure for differentiating bipolar from unipolar mood disorders. Journal of Affective Disorders, 2022, 299, 513-516.	4.1	3
3	Genetic association study reveals impact of interleukin 10 polymorphisms on cognitive functions in schizophrenia. Behavioural Brain Research, 2022, 419, 113706.	2.2	5
4	European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study. Frontiers in Psychiatry, 2022, 13, 826465.	2.6	13
5	Biomarkers of lithium efficacy in bipolar disorders. , 2022, , 293-311.		0
6	Using polygenic scores and clinical data for bipolar disorder patient stratification and lithium response prediction: machine learning approach. British Journal of Psychiatry, 2022, 220, 219-228.	2.8	11
7	Higher indexes of childhood trauma in borderline personality disorder compared with bipolar disorder. Psychiatria Polska, 2022, 56, 7-18.	0.5	3
8	Dysfunction of the Purinergic System in Bipolar Disorder. Neuropsychobiology, 2022, , 1-6.	1.9	0
9	Antiviral, immunomodulatory, and neuroprotective effect of lithium. Journal of Integrative Neuroscience, 2022, 21, 068.	1.7	13
10	Mini-review: Anomalous association between lithium data and lithium use. Neuroscience Letters, 2022, 777, 136590.	2.1	5
11	Lithium. European Neuropsychopharmacology, 2022, 57, 86-87.	0.7	6
12	Speech Understanding in Manic and Depressive Episodes of Mood Disorders. Journal of Neuropsychiatry and Clinical Neurosciences, 2022, 34, 414-421.	1.8	0
13	Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs. European Neuropsychopharmacology, 2022, 60, 91-99.	0.7	9
14	Metabolic indices in schizophrenia: Association of negative symptoms with higher HDL cholesterol in female patients. World Journal of Biological Psychiatry, 2021, 22, 552-556.	2.6	6
15	Genes involved in glucocorticoid receptor signalling affect susceptibility to mood disorders. World Journal of Biological Psychiatry, 2021, 22, 149-160.	2.6	4
16	Association of polygenic score for major depression with response to lithium in patients with bipolar disorder. Molecular Psychiatry, 2021, 26, 2457-2470.	7.9	44
17	Treatment-resistant depression: Neurobiological correlates and the effect of sleep deprivation with sleep phase advance for the augmentation of pharmacotherapy. World Journal of Biological Psychiatry, 2021, 22, 58-69.	2.6	6
18	Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study. CNS Spectrums, 2021, 26, 290-298.	1.2	5

#	Article	IF	CITATIONS
19	Lithium – the benefits of longâ€ŧerm treatment. Bipolar Disorders, 2021, 23, 213-214.	1.9	1
20	Exemplar scoring identifies genetically separable phenotypes of lithium responsive bipolar disorder. Translational Psychiatry, 2021, 11, 36.	4.8	16
21	Prediction of lithium response using genomic data. Scientific Reports, 2021, 11, 1155.	3.3	11
22	Transcriptome Changes in Three Brain Regions during Chronic Lithium Administration in the Rat Models of Mania and Depression. International Journal of Molecular Sciences, 2021, 22, 1148.	4.1	5
23	Differentiating mania/hypomania from happiness using a machine learning analytic approach Journal of Affective Disorders, 2021, 281, 505-509.	4.1	8
24	Lithium therapy in literature and art. Pharmacotherapy in Psychiatry and Neurology, 2021, 36, 271-284.	0.1	0
25	Categorical differentiation of the unipolar and bipolar disorders. Psychiatry Research, 2021, 297, 113719.	3.3	1
26	Etiopathogenesis of schizophrenia – the status of knowledge for 2021. Psychiatria Polska, 2021, 55, 261-274.	0.5	8
27	Transcriptomic profiling as biological markers of depression – A pilot study in unipolar and bipolar women. World Journal of Biological Psychiatry, 2021, 22, 744-756.	2.6	13
28	Etiopathogenesis of bipolar affective illness – the status of knowledge for 2021. Psychiatria Polska, 2021, 55, 481-496.	0.5	6
29	Decreased leucocyte telomere length in male patients with chronic bipolar disorder: lack of effect of long-term lithium treatment. Acta Neuropsychiatrica, 2021, 33, 299-306.	2.1	4
30	Ultra-long-term lithium therapy: all-important matters and a case of successful 50-year lithium treatment. Revista Brasileira De Psiquiatria, 2021, 43, 407-413.	1.7	14
31	Variations in seasonal solar insolation are associated with a history of suicide attempts in bipolar I disorder. International Journal of Bipolar Disorders, 2021, 9, 26.	2.2	6
32	Expression Biomarkers of Pharmacological Treatment Outcomes in Women with Unipolar and Bipolar Depression. Pharmacopsychiatry, 2021, 54, 261-268.	3.3	8
33	HLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders. Scientific Reports, 2021, 11, 17823.	3.3	10
34	Association of Attention-Deficit/Hyperactivity Disorder and Depression Polygenic Scores with Lithium Response: A Consortium for Lithium Genetics Study. Complex Psychiatry, 2021, 7, 80-89.	0.9	6
35	Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients. Translational Psychiatry, 2021, 11, 606.	4.8	25
36	COVID-19 infection in 50 patients receiving lithium. Pharmacotherapy in Psychiatry and Neurology, 2021, 37, .	0.1	1

#	Article	IF	CITATIONS
37	Association of Negative Symptoms of Schizophrenia Assessed by the BNSS and SNS Scales With Neuropsychological Performance: A Gender Effect. Frontiers in Psychiatry, 2021, 12, 797386.	2.6	2
38	International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 921-932.	3.2	22
39	Markers of Regenerative Processes in Patients with Bipolar Disorder: A Case-control Study. Brain Sciences, 2020, 10, 408.	2.3	2
40	The bipolar disorders: A case for their categorically distinct status based on symptom profiles. Journal of Affective Disorders, 2020, 277, 225-231.	4.1	10
41	The psychopathological potential of early life stress. World Journal of Biological Psychiatry, 2020, 21, 491-492.	2.6	Ο
42	Negative symptoms in schizophrenia, assessed by the brief negative symptom scale, self-evaluation of negative symptom scale, and social cognition: a gender effect. International Journal of Psychiatry in Clinical Practice, 2020, 25, 1-6.	2.4	7
43	Lithium – past, present, future. International Journal of Psychiatry in Clinical Practice, 2020, 24, 330-340.	2.4	8
44	Mood Stabilizers: Lithium. , 2020, , 1-30.		2
45	Lithium treatment in the era of personalized medicine. Drug Development Research, 2020, 82, 621-627.	2.9	9
46	Lithium's antiviral effects: a potential drug for CoViD-19 disease?. International Journal of Bipolar Disorders, 2020, 8, 21.	2.2	52
47	A half-century of participant observation in psychiatry. Part I. Schizophrenia. Psychiatria Polska, 2020, 54, 405-419.	0.5	2
48	A severe course of the COVID-19 in a patient receiving prophylactically lithium. Pharmacotherapy in Psychiatry and Neurology, 2020, 36, 143-148.	0.1	3
49	A half-century of participant observation in psychiatry. Part II. Affective illnesses Psychiatria Polska, 2020, 54, 641-659.	0.5	2
50	Lithium treatment – the state of the art for 2020. Psychiatria Polska, 2020, 54, 1047-1066.	0.5	9
51	A half-century of participant observation in psychiatry. Part III: psychopharmacology. Psychiatria Polska, 2020, 54, 845-864.	0.5	1
52	Investigating polygenic burden in age at disease onset in bipolar disorder: Findings from an international multicentric study. Bipolar Disorders, 2019, 21, 68-75.	1.9	20
53	120th Anniversary of the Kraepelinian Dichotomy of Psychiatric Disorders. Current Psychiatry Reports, 2019, 21, 65.	4.5	15
54	Thyroid structure and function in longâ€ŧerm lithiumâ€ŧreated and lithiumâ€naÃ⁻ve bipolar patients. Human Psychopharmacology, 2019, 34, e2708.	1.5	21

#	Article	IF	CITATIONS
55	A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. European Neuropsychopharmacology, 2019, 29, 947-959.	0.7	60
56	Lithium and bipolar depression. Bipolar Disorders, 2019, 21, 458-459.	1.9	4
57	Association between solar insolation and a history of suicide attempts in bipolar I disorder. Journal of Psychiatric Research, 2019, 113, 1-9.	3.1	25
58	No Connection between Long-Term Lithium Treatment and Antithyroid Antibodies. Pharmacopsychiatry, 2019, 52, 232-236.	3.3	14
59	Childhood trauma in mood disorders: Neurobiological mechanisms and implications for treatment. Pharmacological Reports, 2019, 71, 112-120.	3.3	82
60	Augmentation of Pharmacotherapy by Sleep Deprivation with Sleep Phase Advance in Treatment-Resistant Depression. Pharmacopsychiatry, 2019, 52, 186-192.	3.3	14
61	Guides for users and prescribers of lithium. International Journal of Bipolar Disorders, 2019, 7, 29.	2.2	1
62	Recommendations of the Polish Psychiatric Association for treatment of affective disorders in women of childbearing age. Part I: Treatment of depression. Psychiatria Polska, 2019, 53, 245-262.	0.5	8
63	Recommendations of the Polish Psychiatric Association regarding the treatment of affective disorders in women of childbearing age. Part II: Bipolar disorder. Psychiatria Polska, 2019, 53, 263-276.	0.5	7
64	Polish version of the Brief Negative Symptom Scale (BNSS). Psychiatria Polska, 2019, 53, 541-549.	0.5	14
65	Polish version of the Self-evaluation of Negative Symptoms (SNS). Psychiatria Polska, 2019, 53, 551-559.	0.5	13
66	Pharmacotherapy and psychotherapy for bipolar disorder in the context of early childhood trauma. Pharmacotherapy in Psychiatry and Neurology, 2019, 35, 37-50.	0.1	0
67	Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder. JAMA Psychiatry, 2018, 75, 65-74.	11.0	102
68	Genes involved in stress response influence lithium efficacy in bipolar patients. Bipolar Disorders, 2018, 20, 753-760.	1.9	10
69	The role of affective temperaments assessed by the Temperament Evaluation of Memphis, Pisa and San Diego-Autoquestionnaire (TEMPS-A) in the relationship between morningness-eveningness and bipolarity. Journal of Affective Disorders, 2018, 232, 83-88.	4.1	14
70	Meaningful aspects of the term â€~mood stabilizer'. Bipolar Disorders, 2018, 20, 391-392.	1.9	22
71	Clinical Perspectives of Lithium's Neuroprotective Effect. Pharmacopsychiatry, 2018, 51, 194-199.	3.3	38
72	Psychiatric manifestations in Wilson's disease: possibilities and difficulties for treatment. Therapeutic Advances in Psychopharmacology, 2018, 8, 199-211.	2.7	68

#	Article	IF	CITATIONS
73	Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review. Schizophrenia Research, 2018, 192, 16-29.	2.0	138
74	Adult stem cells in psychiatric disorders – New discoveries in peripheral blood. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 23-27.	4.8	9
75	Stem cells, pluripotency and glial cell markers in peripheral blood of bipolar patients on long-term lithium treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 28-33.	4.8	22
76	Are there differences in lipid peroxidation and immune biomarkers between major depression and bipolar disorder: Effects of melancholia, atypical depression, severity of illness, episode number, suicidal ideation and prior suicide attempts. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 372-383.	4.8	82
77	Lipid Peroxidation and Immune Biomarkers Are Associated with Major Depression and Its Phenotypes, Including Treatment-Resistant Depression and Melancholia. Neurotoxicity Research, 2018, 33, 448-460.	2.7	57
78	Internet use by older adults with bipolar disorder: international survey results. International Journal of Bipolar Disorders, 2018, 6, 20.	2.2	13
79	Assessment of Complement Cascade Components in Patients With Bipolar Disorder. Frontiers in Psychiatry, 2018, 9, 614.	2.6	21
80	Mogens Schou (1918â€⊋005): a scientist, a doctor and a lithium champion. Bipolar Disorders, 2018, 20, 680-682.	1.9	0
81	Challenging the Negative Perception of Lithium and Optimizing Its Long-Term Administration. Frontiers in Molecular Neuroscience, 2018, 11, 349.	2.9	39
82	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1173-1182.	2.3	18
83	Wilson disease. Nature Reviews Disease Primers, 2018, 4, 21.	30.5	466
84	Assessment of negative symptoms in male and female schizophrenia patients using the Polish version of the Brief Negative Syndrome Scale and Self-evaluation of Negative Symptoms. Neuropsychiatria I Neuropsychologia, 2018, 13, 121-127.	0.4	1
85	Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder. Frontiers in Psychiatry, 2018, 9, 207.	2.6	28
86	Content overlap analysis of 64 (hypo)mania symptoms among seven common rating scales. International Journal of Methods in Psychiatric Research, 2018, 27, e1737.	2.1	18
87	Commentary: Corroboration of a Major Role for Herpes Simplex Virus Type 1 in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 433.	3.4	5
88	Childhood adversity and clinical features of bipolar mood disorder. Archives of Psychiatry and Psychotherapy, 2018, 20, 13-19.	0.3	9
89	Clinical picture, pathogenesis and psychometric assessment of negative symptoms of schizophrenia. Psychiatria Polska, 2018, 52, 185-197.	0.5	15
90	The effect of long-term lithium treatment of bipolar disorder on stem cells circulating in peripheral blood. World Journal of Biological Psychiatry, 2017, 18, 54-62.	2.6	11

#	Article	IF	CITATIONS
91	Administration of ketamine for unipolar and bipolar depression. International Journal of Psychiatry in Clinical Practice, 2017, 21, 2-12.	2.4	84
92	Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression. International Journal of Psychiatry in Clinical Practice, 2017, 21, 99-103.	2.4	37
93	International multi-site survey on the use of online support groups in bipolar disorder. Nordic Journal of Psychiatry, 2017, 71, 473-476.	1.3	4
94	Morningness–eveningness and affective temperaments assessed by the Temperament Evaluation of Memphis, Pisa and San Diego-Autoquestionnaire (TEMPS-A). Chronobiology International, 2017, 34, 57-65.	2.0	16
95	Associations of Serum Cytokine Receptor Levels with Melancholia, Staging of Illness, Depressive and Manic Phases, and Severity of Depression in Bipolar Disorder. Molecular Neurobiology, 2017, 54, 5883-5893.	4.0	46
96	Increased affective empathy in bipolar patients during a manic episode. Revista Brasileira De Psiquiatria, 2017, 39, 342-345.	1.7	22
97	Postpartum depression: bipolar or unipolar? Analysis of 434 Polish postpartum women. Revista Brasileira De Psiquiatria, 2017, 39, 154-159.	1.7	16
98	Atypical depression: current perspectives. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 2447-2456.	2.2	60
99	Long-term lithium treatment in bipolar disorder: effects on glomerular filtration rate and other metabolic parameters. International Journal of Bipolar Disorders, 2017, 5, 27.	2.2	81
100	Mentalization deficit in bipolar patients during an acute depressive and manic episode: association with cognitive functions. International Journal of Bipolar Disorders, 2017, 5, 38.	2.2	21
101	Regulative theory of temperament versus affective temperaments measured by the temperament evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire (TEMPS-A): a study in a non-clinical Polish sample. Current Issues in Personality Psychology, 2017, 2, 73-82.	0.5	9
102	Recent advances in the understanding and management of bipolar disorder in adults. F1000Research, 2017, 6, 2033.	1.6	14
103	Emotion recognition and theory of mind in chronic schizophrenia: association with negative symptoms. Archives of Psychiatry and Psychotherapy, 2017, 19, 7-12.	0.3	11
104	The Biological Rhythms Interview of Assessment in Neuropsychiatry in patients with bipolar disorder: correlation with affective temperaments and schizotypy. Revista Brasileira De Psiquiatria, 2016, 38, 325-328.	1.7	10
105	Childhood trauma in bipolar disorder. Neuropsychiatria I Neuropsychologia, 2016, 2, 39-46.	0.4	2
106	Editorial: Endophenotypes for Schizophrenia and Mood Disorders: Implications from Genetic, Biochemical, Cognitive, Behavioral, and Neuroimaging Studies. Frontiers in Psychiatry, 2016, 7, 83.	2.6	13
107	Renal sonography in bipolar patients on longâ€ŧerm lithium treatment. Journal of Clinical Ultrasound, 2016, 44, 354-359.	0.8	7
108	The assessment of orthorexia nervosa among 1899 Polish adolescents using the ORTO-15 questionnaire. International Journal of Psychiatry in Clinical Practice, 2016, 20, 199-203.	2.4	54

#	Article	IF	CITATIONS
109	Ketamine Anesthesia, Efficacy of Electroconvulsive Therapy, and Cognitive Functions in Treatment-Resistant Depression. Journal of ECT, 2016, 32, 164-168.	0.6	31
110	Increased mRNA expression of peripheral glial cell markers in bipolar disorder: The effect of long-term lithium treatment. European Neuropsychopharmacology, 2016, 26, 1516-1521.	0.7	14
111	Peripheral mRNA expression of pluripotency markers in bipolar disorder and the effect of long-term lithium treatment. Pharmacological Reports, 2016, 68, 1042-1045.	3.3	6
112	Online information seeking by patients with bipolar disorder: results from an international multisite survey. International Journal of Bipolar Disorders, 2016, 4, 17.	2.2	35
113	A web-based study of bipolarity and impulsivity in athletes engaging in extreme and high-risk sports. Acta Neuropsychiatrica, 2016, 28, 179-183.	2.1	19
114	Internet use by patients with bipolar disorder: Results from an international multisite survey. Psychiatry Research, 2016, 242, 388-394.	3.3	36
115	Relationship of suicide rates with climate and economic variables in Europe during 2000–2012. Annals of General Psychiatry, 2016, 15, 19.	2.7	48
116	Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. Human Molecular Genetics, 2016, 25, 3383-3394.	2.9	182
117	Kidney, thyroid and other organ functions after 40 years or more of lithium therapy: a case series of five patients. Therapeutic Advances in Psychopharmacology, 2016, 6, 277-282.	2.7	19
118	Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet, The, 2016, 387, 1085-1093.	13.7	306
119	Pharmacogenetics of Mood Stabilizers. , 2016, , 93-109.		0
120	Decreased serum zinc concentration during depressive episode in patients with bipolar disorder. Journal of Affective Disorders, 2016, 190, 272-277.	4.1	27
121	Electroconvulsive therapy and cognitive functions in treatment-resistant depression. World Journal of Biological Psychiatry, 2016, 17, 159-164.	2.6	48
122	The effect of lithium on hematopoietic, mesenchymal and neural stem cells. Pharmacological Reports, 2016, 68, 224-230.	3.3	47
123	Depression with atypical features in various kinds of depression. Psychiatria Polska, 2016, 50, 827-838.	0.5	5
124	Negative experiences in childhood and the development and course of bipolar disorder. Psychiatria Polska, 2016, 50, 989-1000.	0.5	16
125	Effect of Lithium on Neurocognitive Functioning. Current Alzheimer Research, 2016, 13, 887-893.	1.4	31
126	The <scp>ADH</scp> gene cluster <scp>SNP</scp> rs1789891 and temperamental dimensions in patients with alcohol dependence and affective disorders. Scandinavian Journal of Psychology, 2015, 56, 420-427.	1.5	5

#	Article	IF	CITATIONS
127	A crossâ€sectional study of thyroid function in 66 patients with bipolar disorder receiving lithium for 10–44Âyears. Bipolar Disorders, 2015, 17, 375-380.	1.9	26
128	Agomelatine-induced liver injury in a patient with choledocholithiasis. Acta Neuropsychiatrica, 2015, 27, 56-59.	2.1	4
129	Psychiatric hospitalizations for affective disorders in Warsaw, Poland: Effect of season and intensity of sunlight. Psychiatry Research, 2015, 229, 287-294.	3.3	37
130	Psychotropic drugs and personality changes: A case of lithium. Pharmacological Reports, 2015, 67, 1204-1207.	3.3	4
131	Atypical features in depression: Association with obesity and bipolar disorder. Journal of Affective Disorders, 2015, 185, 76-80.	4.1	44
132	Neurobiology and temperament in the offspring of excellent lithium responders. World Journal of Biological Psychiatry, 2015, 16, 272-277.	2.6	5
133	Influence of light exposure during early life on the age of onset of bipolar disorder. Journal of Psychiatric Research, 2015, 64, 1-8.	3.1	39
134	Temperamental dimensions of the TEMPS-A in male and female subjects engaging in extreme or/and high risk sports. Journal of Affective Disorders, 2015, 170, 66-70.	4.1	17
135	Sleep deprivation as a method of chronotherapy in the treatment of depression. Psychiatria Polska, 2015, 49, 423-433.	0.5	19
136	Symptoms of depression among adults in rural areas of western Poland. Annals of Agricultural and Environmental Medicine, 2015, 22, 152-155.	1.0	2
137	Factors Associated with Lithium Efficacy in Bipolar Disorder. Harvard Review of Psychiatry, 2014, 22, 353-357.	2.1	30
138	Suicidal behaviour and lipid levels in unipolar and bipolar depression. Acta Neuropsychiatrica, 2014, 26, 315-320.	2.1	24
139	Prophylactic lithium treatment and cognitive performance in patients with a long history of bipolar illness: no simple answers in complex disease-treatment interplay. International Journal of Bipolar Disorders, 2014, 2, 1.	2.2	28
140	Polymorphism of circadian clock genes and prophylactic lithium response. Bipolar Disorders, 2014, 16, 151-158.	1.9	58
141	Polymorphism of circadian clock genes and temperamental dimensions of the TEMPS-A in bipolar disorder. Journal of Affective Disorders, 2014, 159, 80-84.	4.1	39
142	Stratified medicine for mental disorders. European Neuropsychopharmacology, 2014, 24, 5-50.	0.7	152
143	Extrapyramidal symptoms during treatment of first schizophrenia episode: Results from EUFEST. European Neuropsychopharmacology, 2014, 24, 1500-1505.	0.7	25
144	Response to Lithium in Bipolar Disorder: Clinical and Genetic Findings. ACS Chemical Neuroscience, 2014, 5, 413-421.	3.5	64

9

#	Article	IF	CITATIONS
145	The prevalence of antipsychotic polypharmacy in schizophrenic patients discharged from psychiatric units in Poland. Pharmacological Reports, 2014, 66, 613-617.	3.3	15
146	Postpartum depression: Identifying associations with bipolarity and personality traits. Preliminary results from a cross-sectional study in Poland. Psychiatry Research, 2014, 215, 69-74.	3.3	25
147	Temperamental dimensions of the TEMPS-A in females with co-morbid bipolar disorder and bulimia. Journal of Affective Disorders, 2014, 164, 90-93.	4.1	13
148	Relationship between sunlight and the age of onset of bipolar disorder: An international multisite study. Journal of Affective Disorders, 2014, 167, 104-111.	4.1	43
149	Suicidal Behavior in Schizophrenia may be Related to Low Lipid Levels. Medical Science Monitor, 2014, 20, 1486-1490.	1.1	27
150	The effect of lithium on thyroid function in patients with bipolar disorder Psychiatria Polska, 2014, 48, 417-428.	0.5	17
151	The association of glycogen synthase kinase-3beta (CSK-3β) gene polymorphism with kidney function in long-term lithium-treated bipolar patients. International Journal of Bipolar Disorders, 2013, 1, 8.	2.2	22
152	Genetic Influences on Response to Mood Stabilizers in Bipolar Disorder. CNS Drugs, 2013, 27, 165-173.	5.9	66
153	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. American Journal of Psychiatry, 2013, 170, 1249-1262.	7.2	579
154	Stability of lithium treatment in bipolar disorder - long-term follow-up of 346 patients. International Journal of Bipolar Disorders, 2013, 1, 11.	2.2	22
155	Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved?. Human Psychopharmacology, 2013, 28, 87-90.	1.5	78
156	TEMPS-A and long-term lithium response: Positive correlation with hyperthymic temperament. Journal of Affective Disorders, 2013, 145, 187-189.	4.1	57
157	Increased serum matrix metalloproteinase-9 (MMP-9) levels in young patients during bipolar depression. Journal of Affective Disorders, 2013, 146, 286-289.	4.1	62
158	Possible usefulness of tianeptine in treatment-resistant depression. International Journal of Psychiatry in Clinical Practice, 2013, 17, 313-316.	2.4	12
159	Novel markers of kidney injury in bipolar patients on longâ€ŧerm lithium treatment. Human Psychopharmacology, 2013, 28, 615-618.	1.5	19
160	Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. PLoS ONE, 2013, 8, e65636.	2.5	156
161	Functional –1149 G/T Polymorphism of the Prolactin Gene in Schizophrenia. Neuropsychobiology, 2012, 65, 41-44.	1.9	17
162	Treatment of depression in first episode of schizophrenia: Results from EUFEST. European Neuropsychopharmacology, 2012, 22, 875-882.	0.7	22

#	Article	IF	CITATIONS
163	Clinical and pathogenic aspects of candidate genes for lithium prophylactic efficacy. Journal of Psychopharmacology, 2012, 26, 368-373.	4.0	54
164	Selected Cytokine Profiles during Remission in Bipolar Patients. Neuropsychobiology, 2012, 66, 193-198.	1.9	37
165	Bipolarity and inadequate response to antidepressant drugs: Clinical and psychopharmacological perspective. Journal of Affective Disorders, 2012, 136, e13-e19.	4.1	39
166	Screening for the markers of kidney damage in men and women on long-term lithium treatment. Medical Science Monitor, 2012, 18, CR656-CR660.	1.1	14
167	Lithium in neuropsychiatry: A 2010 update. World Journal of Biological Psychiatry, 2011, 12, 340-348.	2.6	43
168	Painting "Mania― Journal of Affective Disorders, 2011, 128, 319-320.	4.1	3
169	Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene and response to lithium prophylaxis in bipolar patients. Human Psychopharmacology, 2011, 26, 168-171.	1.5	18
170	Bipolar Mood Disorder, Creativity and Schizotypy: An Experimental Study. Psychopathology, 2011, 44, 296-302.	1.5	40
171	Glucocorticoid receptor polymorphism is associated with lithium response in bipolar patients. Neuroendocrinology Letters, 2011, 32, 545-51.	0.2	12
172	Polish version of the Hypomania Checklist (HCL-32) scale: the results in treatment-resistant depression. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 139-144.	3.2	33
173	Polish validation of the TEMPS-A: The profile of affective temperaments in a college student population. Journal of Affective Disorders, 2010, 123, 36-41.	4.1	61
174	The utility of Mood Disorder Questionnaire for the detection of bipolar diathesis in treatment-resistant depression. Journal of Affective Disorders, 2010, 124, 270-274.	4.1	26
175	The International Consortium on Lithium Genetics (ConLiGen): An Initiative by the NIMH and IGSLI to Study the Genetic Basis of Response to Lithium Treatment. Neuropsychobiology, 2010, 62, 72-78.	1.9	134
176	Excellent lithium responders have normal cognitive functions and plasma BDNF levels. International Journal of Neuropsychopharmacology, 2010, 13, 617-622.	2.1	94
177	Anticholinergic Mechanisms. Journal of Clinical Psychiatry, 2010, 71, 1698-1700.	2.2	3
178	Matrix Metalloproteinase-9 (MMP9)—A Mediating Enzyme in Cardiovascular Disease, Cancer, and Neuropsychiatric Disorders. Cardiovascular Psychiatry and Neurology, 2009, 2009, 1-7.	0.8	61
179	<i>FYN</i> Kinase Gene: Another Glutamatergic Gene Associated with Bipolar Disorder?. Neuropsychobiology, 2009, 59, 178-183.	1.9	28
180	Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST). American Journal of Psychiatry, 2009, 166, 675-682.	7.2	284

#	Article	IF	CITATIONS
181	The association study of three <i>FYN</i> polymorphisms with prophylactic lithium response in bipolar patients. Human Psychopharmacology, 2009, 24, 287-291.	1.5	26
182	Matrix Metalloproteinase-9 Gene and Bipolar Mood Disorder. NeuroMolecular Medicine, 2009, 11, 128-132.	3.4	43
183	Functional polymorphism of the matrix metalloproteinase-9 (MMP-9) gene in schizophrenia. Schizophrenia Research, 2009, 109, 90-93.	2.0	74
184	No association of three GRIN2B polymorphisms with lithium response in bipolar patients. Pharmacological Reports, 2009, 61, 448-452.	3.3	26
185	Response to prophylactic lithium in bipolar disorder may be associated with a preservation of executive cognitive functions. European Neuropsychopharmacology, 2009, 19, 791-795.	0.7	41
186	Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet, The, 2008, 371, 1085-1097.	13.7	964
187	Association studies of the <i>BDNF</i> and the <i>NTRK2</i> gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics, 2008, 9, 1595-1603.	1.3	73
188	Aripiprazole Joins the Family of Second-Generation Mood Stabilizers. Journal of Clinical Psychiatry, 2008, 69, 862-863.	2.2	9
189	Types of Depression More Frequent in Bipolar than in Unipolar Affective Illness: Results of the Polish DEP-BI Study. Psychopathology, 2007, 40, 153-158.	1.5	49
190	Two generations of mood stabilizers. International Journal of Neuropsychopharmacology, 2007, 10, 709-11.	2.1	33
191	Response to lithium prophylaxis: Interaction between serotonin transporter and <i>BDNF</i> genes. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 820-823.	1.7	77
192	Long-term administration of the low-dose risperidone in schizotaxia subjects. Human Psychopharmacology, 2007, 22, 407-412.	1.5	8
193	Long-term pharmacological treatment of bipolar disorders. Neuroendocrinology Letters, 2007, 28 Suppl 1, 71-93.	0.2	0
194	Association study of the glycogen synthase kinase-3β gene polymorphism with prophylactic lithium response in bipolar patients. World Journal of Biological Psychiatry, 2006, 7, 158-161.	2.6	64
195	Impairment of Endothelial Function in Unipolar and Bipolar Depression. Biological Psychiatry, 2006, 60, 889-891.	1.3	89
196	Performance on the Wisconsin Card Sorting Test in schizophrenia and genes of dopaminergic inactivation (COMT, DAT, NET). Psychiatry Research, 2006, 143, 13-19.	3.3	45
197	Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brainâ€derived neurotrophic factor gene. Psychiatry and Clinical Neurosciences, 2006, 60, 70-76.	1.8	105
198	Bipolar mood disorders among Polish psychiatric outpatients treated for major depression. Journal of Affective Disorders, 2005, 84, 141-147.	4.1	66

#	Article	IF	CITATIONS
199	Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype. Pharmacological Reports, 2005, 57, 124-7.	3.3	51
200	Association studies of 5-HT2A and 5-HT2C serotonin receptor gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacological Reports, 2005, 57, 761-5.	3.3	27
201	Long-term assessment of the efficacy and tolerability of risperidone in early schizophrenia: An international multicenter study. International Journal of Psychiatry in Clinical Practice, 2004, 8, 147-152.	2.4	2
202	Association analysis of the insertion/deletion polymorphism in serotonin transporter gene in patients with affective disorder. European Psychiatry, 2003, 18, 129-132.	0.2	58
203	The prophylactic effect of longâ€ŧerm lithium administration in bipolar patients entering treatment in the 1970s and 1980s. Bipolar Disorders, 2001, 3, 63-67.	1.9	88
204	Rates of flu-like infection in patients with affective illness. Journal of Affective Disorders, 1998, 47, 177-182.	4.1	16
205	FREE-THYROXINE INDEX AND ABSOLUTE FREE-THYROXINE IN AFFECTIVE DISORDERS. Lancet, The, 1973, 301, 889.	13.7	23